-+ 0.00%
-+ 0.00%
-+ 0.00%

Neumora Therapeutics presents preclinical NMRA-215 data showing up to 19% weight loss in obese mice

PUBT·11/16/2026 13:17:08
Neumora Therapeutics presents preclinical NMRA-215 data showing up to 19% weight loss in obese mice
  • Neumora Therapeutics presented nonclinical data supporting advancement of obesity candidate NMRA-215 into clinical studies.
  • In obese mice, NMRA-215 produced up to 19% weight loss alone and up to 26% with semaglutide.
  • One three-month rat toxicity study showed unexpected adverse findings; an audit identified critical discrepancies, while a second study supported clinical development.
  • For Alzheimer's disease agitation, NMRA-511 will enter Phase 2 testing at 20 mg and 30 mg twice daily.
  • Phase 1b showed reduced agitation scores, with larger effects in patients with elevated anxiety; the study was not powered for statistical significance.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neumora Therapeutics Inc published the original content used to generate this news brief on November 16, 2026, and is solely responsible for the information contained therein.